Cannabis and schizophrenia: New findings in an old debate;Cannabis und Schizophrenie: Neue erkenntnisse in einer alten debatte

Neuropsychiatrie

Volumn 22, Issue 4, 2008, Pages 223-229

  Kawohl, Wolfram ^a,b   Rössler, Wulf ^a,b  

^a Forschungsgruppe Klinische und Experimentelle Psychopathologie ^*

^b UNIVERSITY HOSPITAL OF PSYCHIATRY   (Switzerland)

Author keywords

Cannabis; Causality; Psychosis; Schizophrenia; Tetrahydrocannabinol

Indexed keywords

CANNABIDIOL; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABIS; CATECHOL METHYLTRANSFERASE; NEUROTRANSMITTER; PLACEBO; RIMONABANT;

AUDITORY HALLUCINATION; BRAIN; CANNABIS ADDICTION; CAUSAL ATTRIBUTION; CLINICAL TRIAL; COHORT ANALYSIS; DEPERSONALIZATION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOPAMINERGIC TRANSMISSION; DRUG EFFECT; ELECTROPHYSIOLOGY; EPIDEMIOLOGICAL DATA; GABAERGIC TRANSMISSION; GENETIC ASSOCIATION; HIGH RISK POPULATION; HUMAN; INCIDENCE; LOW DRUG DOSE; NEUROBIOLOGY; PRESYNAPTIC NERVE; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; VISUAL HALLUCINATION;

CAUSALITY; COMORBIDITY; CROSS-SECTIONAL STUDIES; HUMANS; INCIDENCE; MARIJUANA ABUSE; PSYCHOSES, SUBSTANCE-INDUCED; RISK; SCHIZOPHRENIA; TETRAHYDROCANNABINOL;

EID: 58149326830     PISSN: 09486259     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Ajdacic-Gross V., Lauber C., Warnke I., Haker H., Murray R.M., Rossler W.: Changing incidence of psychotic disorders among the young in Zurich. Schizophr Res 95, 9-18 (2007).
2. Akil M, Kolachana B.S., Rothmond D.A., Hyde T.M., Weinberger D.R., Kleinman J.E.: Catechol-O-methyltransferase genotype and dopamine regulation in the human brain. J Neurosci 23, 2008-2013 (2003).
3. Ames F.R.: A clinical and metabolic study of acute intoxication with Cannabis sativa and its role in the model psychoses. J Mental Sci 104, 972-999 (1958).
4. Andreasson S., Allebeck P., Engstrom A., Rydberg U.: Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet 2, 1483-1486 (1987).
5. Arseneault L., Cannon M., Poulton R., Murray R., Caspi A., Moffitt T.E.: Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. Bmj 325, 1212-1213. (2002).
6. Arseneault L., Cannon M., Witton J., Murray R.M.: Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry 184, 110-117 (2004).
7. Bilder R.M., Volavka J., Lachman H.M., Grace A.A.: The catechol-O-methyltransferase polymorphism: relations to the tonic-phasic dopamine hypothesis and neuropsychiatric phenotypes. Neuropsychopharmacology 29, 1943-1961 (2004).
8. Bortolato M., Aru G.N., Frau R., Orru M., Luckey G.C., Boi G., Gessa G.L.: The CB receptor agonist WIN 55,212-2 fails to elicit disruption of prepulse inhibition of the startle in Sprague-Dawley rats. Psychopharmacology (Berl) 177, 264-271 (2005).
9. Caspi A., Moffitt T.E., Cannon M., McClay J., Murray R., Harrington H., Taylor A., Arseneault L., Williams B., Braithwaite A., Poulton R., Craig I.W.: Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry 57, 1117-1127 (2005).
10. Cheer J.F., Wassum K.M., Heien M.L., Phillips P.E., Wightman R.M.: Cannabinoids enhance subsecond dopamine release in the nucleus accumbens of awake rats. J Neurosci 24, 4393-4400 (2004).
11. Chen J., Marmur R., Pulles A., Paredes W., Gardner E.L.: Ventral tegmental microinjection of delta 9-tetrahydrocannabinol enhances ventral tegmental somatodendritic dopamine levels but not forebrain dopamine levels: evidence for local neural action by marijuana's psychoactive ingredient. Brain Res 621, 65-70 (1993).
12. Dean B., Sundram S., Bradbury R., Scarr E., Copolov D.: Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience 103, 9-15 (2001).
13. Degenhardt L., Hall W., Lynskey M.: Exploring the association between cannabis use and depression. Addiction 98, 1493-1504 (2003).
14. Egertova M., Giang D.K., Cravatt B.F., Elphick M.R.: A new perspective on cannabinoid signalling: complementary localization of fatty acid amide hydrolase and the CB1 receptor in rat brain. Proc Biol Sci 265, 2081-2085 (1998).
15. Ferdinand R.F., Sondeijker F., van der Ende J., Selten J.P., Huizink A., Verhulst F.C.: Cannabis use predicts future psychotic symptoms, and vice versa. Addiction 100, 612-618 (2005).
16. Fergusson D.M., Honvood L.J., Ridder E.M.: Tests of causal linkages between cannabis use and psychotic symptoms. Addiction 100, 354-366 (2005).
17. Gorriti M.A., Rodriguez de Fonseca F., Navarro M., Palomo T.: Chronic (-)-delta9-tetrahydrocannabinol treatment induces sensitization to the psychomotor effects of amphetamine in rats. Eur J Pharmacol 365, 133-142 (1999).
18. Hall W., Degenhardt L.: Cannabis use and the risk of developing a psychotic disorder. World Psychiatry 7, 68-71 (2008).
19. Hambrecht M., Hafner H.: Substance abuse and the onset of schizophrenia. Biol Psychiatry 40, 1155-1163 (1996).
20. Henquet C., Krabbendam L., Spauwen J., Kaplan C., Lieb R., Wittchen H.U., van Os J.: Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. Bmj 330, 11 (2005).
21. Henquet C., Murray R., Linszen D., van Os J.: The environment and schizophrenia: the role of cannabis use. Schizophr Bull 31, 608-612 (2005).
22. Henquet C., Rosa A., Krabbendam L., Papiol S., Fananas L., Drukker M., Ramaekers J.G., van Os J.: An experimental study of catechol-o- methyltransferase Val158Met moderation of delta-9-tetrahydrocannabinol-induced effects on psychosis and cognition. Neuropsychopharmacology 31, 2748-2757 (2006).
23. Herkenham M., Lynn A.B., Little M.D., Johnson M.R., Melvin L.S., de Costa B.R., Rice K.C.: Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A 87, 1932-1936 (1990).
24. Huestis M.A., Gorelick D.A., Heishman S.J., Preston K.L., Nelson R.A., Moolchan E.T., Frank R.A.: Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Arch Gen Psychiatry 58, 322-328 (2001).
25. Isbell H., Gorodetzsky C.W., Jasinski D., Claussen U., von Spulak F., Korte F.: Effects of (-)delta-9-trans-tetrahydrocannabinol in man. Psychopharmacologia 11, 184-188 (1967).
26. Iversen L.: How cannabis works in the brain. In: D. Castle and R. Murrays: Marijuana and Madness. Cambridge University Press, Cambridge 2004
27. Johns A.: Psychiatric effects of cannabis. Br J Psychiatry 178, 116-122 (2001).
28. Johns A.: Psychiatric effects of cannabis. Br J Psychiatry 178, 116-122. (2001).
29. Juckel G., Kawohl W., Giegling I., Mavrogiorgou P., Winter C., Pogarell O., Mulert C., Hegerl U., Rujescu D.: Association of catechol-O-methyltransferase variants with loudness dependence of auditory evoked potentials. Hum Psychopharmacot 23, 115-120 (2008).
30. Macleod J., Oakes R., Copello A., Crome I., Egger M., Hickman M., Oppenkowski T., Stokes-Lampard H., Davey Smith G.: Psychological and social sequelae of cannabis and other illicit drug use by young people: a systematic review of longitudinal, general population studies. Lancet 363, 1579-1588 (2004).
31. Mechoulam R., Gaoni Y.: A Total Synthesis of Dl-Delta-1- Tetrahydrocannabinol, the Active Constituent of Hashish. J Am Chem Soc 87, 3273-3275 (1965).
32. Meyer-Lindenberg A., Kohn P.D., Kolachana B., Kippenhan S., McInerney-Leo A., Nussbaum R., Weinberger D.R., Berman K.F.: Midbrain dopamine and prefrontal function in humans: interaction and modulation by COMT genotype. Nat Neurosci 8, 594-596 (2005).
33. Moore T.H., Zammit S., Lingford-Hughes A., Barnes T.R., Jones P.B., Burke M., Lewis G.: Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 370, 319-328 (2007).
34. Munro S., Thomas K.L., Abu-Shaar M.: Molecular characterization of a peripheral receptor for cannabinoids. Nature 365, 61-65 (1993).
35. Murray R.M., Morrison P.D., Henquet C., Di Forti M.: Cannabis, the mind and society: the hash realities. Nat Rev Neurosci 8, 885-895 (2007).
36. O'Shea M, McGregor I.S., Mallet P.E.: Repeated cannabinoid exposure during perinatal, adolescent or early adult ages produces similar longlasting deficits in object recognition and reduced social interaction in rats. J Psychopharmacol 20, 611-621 (2006).
37. Parnefjord R.: Das Drogentaschenbuch. Thieme, Stuttgart, New York (2000)
38. Pistis M., Ferraro L., Pira L., Flore G., Tanganelli S., Gessa G.L., Devoto P.: Delta(9)-tetrahydrocannabinol decreases extracellular GABA and increases extracellular glutamate and dopamine levels in the rat prefrontal cortex: an in vivo microdialysis study. Brain Res 948, 155-158 (2002).
39. Rätsch C.: Enzyklopädie der psychoaktiven Pflanzen: Botanik, Ethnopharmakologie und Anwendungen. AT Verlag, Aarau 2004
40. Rodriguez de Fonseca F., Del Arco I., Bermudez-Silva F.J., Bilbao A., Cippitelli A., Navarro M.: The endocannabinoid system: physiology and pharmacology. Alcohol Alcohol 40, 2-14 (2005).
41. Roser P., Juckel G., Rentzsch J., Nadulski T., Gallinat J., Stadelmann A.M.: Effects of acute oral Delta(9)-tetrahydrocannabinol and standardized cannabis extract on the auditory P300 event-related potential in healthy volunteers. Eur Neuropsychopharmacol 18, 569-577 (2008).
42. Roser P., Vollenweider F.X., Kawohl W.: Potential antipsychotic properties of central cannabinoid (CBl) receptor antagonists. World Journal of Biological Psychiatry epub ahead of print, 10.1080/15622970801908047 (2008).
43. Rothman K.J.: Interactions between causes. In: Modern Epidemiology. Little, Brown and Co., Boston 1986
44. Schneider M., Koch M.: Chronic pubertal, but not adult chronic cannabinoid treatment impairs sensorimotor gating, recognition memory, and the performance in a progressive ratio task in adult rats. Neuropsychopharmacology 28, 1760-1769 (2003).
45. Semple D.M., McIntosh A.M., Lawrie S.M.: Cannabis as a risk factor for psychosis: systematic review. J Psychopharmacol 19, 187-194 (2005).
46. Sundram S., Copolov D., Dean B.: Clozapine decreases [3H] CP 55940 binding to the cannabinoid 1 receptor in the rat nucleus accumbens. Naunyn Schmiedebergs Arch Pharmacol 371, 428-433 (2005).
47. Tien A.Y., Anthony J.C.: Epidemiological analysis of alcohol and drug use as risk factors for psychotic experiences. J Nerv Ment Dis 178, 473-480 (1990).
48. Uslaner J.M., Norton C.S., Watson S.J., Akil H., Robinson T.E.: Amphetamine-induced c-fos mRNA expression in the caudate-putamen and subthalamic nucleus: interactions between dose, environment, and neuronal phenotype. J Neurochem 85, 105-114 (2003).
49. van Os J., Bak M., Hanssen M., Bijl R.V., de Graaf R., Verdoux H.: Cannabis use and psychosis: a longitudinal population-based study. Am J Epidemiol 156, 319-327 (2002).
50. Wiles N.J., Zammit S., Bebbington P., Singleton N., Meltzer H., Lewis G.: Self-reported psychotic symptoms in the general population: results from the longitudinal study of the British National Psychiatric Morbidity Survey. Br J Psychiatry 188, 519-526 (2006).
51. Witton J., Murray R.M.: [Reefer madness revisited: cannabis and psychosis]. Rev Bras Psiquiatr 26, 2-3 (2004).
52. Zammit S., Allebeck P., Andreasson S., Lundberg I., Lewis G.: Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. Bmj 325, 1199 (2002).
53. Zammit S., Spurlock G., Williams H., Norton N., Williams N., O'Donovan M.C., Owen M.J.: Genotype effects of CHRNA7, CNR1 and COMT in schizophrenia: interactions with tobacco and cannabis use. Br J Psychiatry 191, 402-407 (2007).
54. Zuardi A.W., Crippa J.A., Hallak J.E., Moreira F.A., Guimaraes F.S.: Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Braz J Med Biol Res 39, 421-429 (2006).